-+ 0.00%
-+ 0.00%
-+ 0.00%
Chosa Oncology Enters Global Cross-Licensing Partnership With AIDA Oncology
Share
Listen to the news
Chosa Oncology Enters Global Cross-Licensing Partnership With AIDA Oncology
  • Chosa Oncology entered a global, reciprocal, nonexclusive licensing partnership with AIDA Oncology on Aug. 27, 2026.
  • AIDA gained rights to use Platin-DRP in breast cancer; Chosa received rights to use TaxaTect in lung cancer.
  • The agreement includes undisclosed per-test fees.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending